NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Question: 1 / 1820

What is the primary disease-modifying antirheumatic drug (DMARD) for sickle cell disease?

Methotrexate

Leflunomide

Hydroxyurea

Hydroxyurea is the primary disease-modifying antirheumatic drug (DMARD) for sickle cell disease. This is because it helps to reduce the frequency of pain crises and progression of organ damage caused by sickle cell disease. Methotrexate and sulfasalazine are commonly used as DMARDs for other autoimmune conditions such as rheumatoid arthritis, but they are not effective for treating sickle cell disease. Leflunomide is also used as a DMARD for rheumatoid arthritis, but has not been proven to be effective for sickle cell disease. Therefore, hydroxyurea is the most appropriate DMARD for treating sickle cell disease.

Get further explanation with Examzify DeepDiveBeta

Sulfasalazine

Next Question

Report this question

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy